PDCD1 and autoimmune hemolytic anemia: Moreover, ICIs can induce warm antibody AIHA by augmenting or redirecting immune surveillance [99], and the risk of AIHA is greater with PD-1 or PD-L1 monoclonal therapy than with CTLA-4-inhibitor treatment [100].